Abstract

A metabolic illness that affects around 25% of the world's population, metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with numerous more ailments. It is associated with dementia progression, influenced by factors like brain insulin resistance, cerebrovascular dysfunction, gut dysbiosis, and neuroinflammation. Furthermore, other MASLD characteristics like systemic inflammation, vascular dysfunction, and sleep apnea are also strongly linked to cognitive dysfunction. Recent research suggests MASLD could contribute to cognitive impairment even without these factors. As dementia and MASLD share clinical characteristics and underlying metabolic risk factors, further research is needed to find effective treatments for both. This study discusses the shared pathogenic traits and mechanisms of dementia and MASLD. Additionally, this review discusses various non-medication and medication treatment strategies along with the different types of nano formulation studies for the treatment of MASLD.

Keywords: Cognitive dysfunction, cerebrovascular dysfunction, gut dysbiosis, nano formulations, metabolic dysfunction, steatotic liver disease.